Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lowered by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. reduced its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 286,756 shares of the pharmaceutical company’s stock after selling 9,812 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.11% of Vertex Pharmaceuticals worth $115,477,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in VRTX. Northwest Investment Counselors LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $25,000. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $27,000. Dunhill Financial LLC raised its holdings in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares during the period. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $33,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $35,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $440.68 on Wednesday. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The firm’s fifty day simple moving average is $434.75 and its 200 day simple moving average is $463.64. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $113.49 billion, a PE ratio of -221.45, a PEG ratio of 2.20 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same period last year, the business posted $3.67 EPS. Vertex Pharmaceuticals’s revenue was up 11.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Truist Financial cut their price target on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. Bank of America cut their price target on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a report on Thursday, December 19th. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 20th. Piper Sandler cut their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $494.76.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.